aap Implantate AG (" aap ") announces the market launch of its innovative periprosthetic LOQTEQ® system with the distal lateral femur plate 4.5 PP (periprosthetic). The system is based on a new patent pending fixation technology and enables the treatment of bone fractures in the immediate vicinity of joint implants already existing in the body. Thereby the periprosthetic LOQTEQ® system addresses one of the most demanding procedures in orthopaedics. The distal lateral femur plate 4.5 PP has a CE mark.Implantations of artificial hip and knee joints are among the most frequent procedures in Germany. With such implantations bone fractures can occur in the immediate vicinity of the treated site during the life of the used joint implants. Treating such fractures poses a particular challenge in orthopaedics because the screws for the bone plates must be fixed around the joint implant. This is where aap 's periprosthetic LOQTEQ® system becomes effective with its innovative fixation technology. The core of the new technology are special LOQTEQ® hinges that can be fixed to the plate both distally and proximally. They remain flexible within a 45° angle range and are anchored in the bone at a variable angle (±15°) by angle-stable 3.5 mm screws. In this way the fixation can be adapted for a wide range of bone diameters and the plates can be securely fixed past a prosthesis or a nail, especially in an osteoporotic bone. The hinges ensure that the surgeon has maximum flexibility in planning and carrying out the operational stabilisation by means of optional use at the proximal and distal end of the plate. aap' s offering in this area is complemented by cerclage trays for cable or wire cerclages. In recent months the periprosthetic LOQTEQ® system has proven its worth in clinical initial applications in respect of user friendliness and flexibility. In the future, aap plans to extend the periprosthetic fixation technology to other relevant plates in the LOQTEQ® portfolio for different anatomical regions.
aap Implantate AG is a globally operating medical device company headquartered in Berlin, Germany. The company develops, manufactures and markets trauma products for orthopaedics. The IP protected portfolio includes besides the innovative anatomical plating system LOQTEQ® and trauma complementary biomaterials a wide range of cannulated screws as well as standard plates and screws. Furthermore, aap Implantate AG has an innovation pipeline with promising development projects as the antibacterial silver coating technology and magnesium based implants. These technologies address critical problems in surgery that haven't yet been resolved adequately. In German-speaking Europe aap Implantate AG directly sells its products to hospitals, buying syndicates and hospital groups while it uses a broad network of distributors in more than 25 countries at the international level. aap Implantate AG's stock is listed in the Prime Standard segment of Frankfurt Stock Exchange (XETRA: AAQ.DE). For more information, please visit www.aap.de, or download the Company's investor relations app from the Apple's App Store or Google Play.
This release may contain forward-looking statements based on current experience, estimates and projections of the management board and currently available information. They are not guarantees of future performance. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. Many factors could cause the actual results, performance or achievements of aap to be materially different from those that may be expressed or implied by such statements. These factors include those discussed in aap 's public reports. Forward-looking statements therefore speak only as of the date they are made. aap does not assume any obligation to update the forward-looking statements contained in this release or to conform them to future events or developments.
For inquiries please contact:
Implantate AG, Fabian Franke, Investor Relations, Lorenzweg 5, 12099 Berlin, Germany
Tel.: +49 30 7501 9-134, fax: +49 30 7501 9-290, e-mail: email@example.com
Last updated on: 15/10/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.